Flamel Technologies Announces Public Release of Phase IIa data on Basu

    Pharmaceutical Writers/Business Editors/Health Editors/Medical
    Editors

    LYON, France--(BUSINESS WIRE)--Feb. 7, 2005--Flamel Technologies (NASDAQ:FLML) announced today that it has posted a summary of Phase IIa data conducted on Flamel's long-acting insulin, Basulin(R), on its website.
    "We are pleased with the results of the Phase IIa obtained on thirty (30) Type I diabetic patients. This study confirms our strong expectations for Basulin(R) because Medusa(R), our nano-particulate system, is the only one capable to deliver human insulin with this level of efficacy," said Dr. Gerard Soula, founder, president and chief executive officer of Flamel Technologies, S.A. "We are actively looking for a partner capable of realizing the full development and commercialization of Basulin(R)".
    Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Flamel's Medusa(R) technology is designed to deliver therapeutic proteins. Micropump(R) is a controlled release and taste-masking technology for the oral administration of small molecule drugs.
    This document contains a number of matters, particularly as related to the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
    The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.
    These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances.
    These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2003.

--30--TG/ph*

CONTACT: Flamel Technologies S.A. Gerard Soula, (33) 4-72-78-34-34 Fax: (33) 4-72-78-34-35 Soula@flamel.com or Stephen H. Willard, 202-862-3993 Fax: 202-862-3933 Willard@flamel.com or Charles Marlio, 202-862-8535 Fax: 202-862-3933 Marlio@flamel.com

KEYWORD: DISTRICT OF COLUMBIA FRANCE INTERNATIONAL EUROPE INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY PRODUCT SOURCE: Flamel Technologies S.A.

Copyright Business Wire 2005